News stories about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat negative this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a news impact score of 0.00 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.9600648629817 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of brokerages have issued reports on CNCE. Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Concert Pharmaceuticals in a research note on Monday, September 18th. Finally, BidaskClub downgraded shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $24.60.
Concert Pharmaceuticals (NASDAQ CNCE) traded down 0.40% on Thursday, hitting $14.91. 53,401 shares of the stock were exchanged. The company has a 50-day moving average price of $14.92 and a 200-day moving average price of $14.75. Concert Pharmaceuticals has a 52-week low of $7.11 and a 52-week high of $19.11. The firm’s market cap is $338.26 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.04. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts anticipate that Concert Pharmaceuticals will post ($2.18) EPS for the current fiscal year.
In other news, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $14.51, for a total transaction of $50,785.00. Following the completion of the transaction, the insider now owns 9,500 shares of the company’s stock, valued at $137,845. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.10% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/10/13/concert-pharmaceuticals-cnce-receiving-somewhat-critical-press-coverage-study-shows.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.